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Abstract
Fatigue is described as a dominant and disturbing symptom of rheumatoid arthritis (RA) regardless of the advances in 
pharmacological treatment. Fatigue is also found to correlate with depression. The objective was to evaluate the impact of 
moderate-to-high intensity, aerobic and resistance exercise with person-centered guidance on fatigue, anxiety and depres-
sion, in older adults with RA. Comparisons were made between older adults (> 65 years) with RA taking part in a 20-week 
moderate-to-high intensity exercise at a gym (n = 36) or in home-based exercise of light intensity (n = 38). Assessments 
were performed at baseline, at 20 weeks, and at 52 weeks. Outcomes were differences in Multidimensional Fatigue Inven-
tory (MFI-20), Visual Analog Scale Fatigue (VAS fatigue), and Hospital Anxiety and Depression Scale (HADS). Analysis 
of metabolomics was also performed. The subscales “physical fatigue” and “mental fatigue” in MFI-20 and symptoms of 
depression using HADS depression scale improved significantly at week 20 in the exercise group compared with the control 
group. Exercise did not influence global fatigue rated by VAS or subscales “reduced motivation”, “reduced activity” and 
“general fatigue” in MFI-20. No significant change was found on the anxiety index of HADS. The improvements in physical 
fatigue were associated with changes in the metabolism of lipids, bile acids, the urea cycle and several sugars. Moderate-
to-high intensity exercise with person-centered guidance decreased fatigue and improved symptoms of depression and were 
accompanied by metabolic changes in older adults with RA.
Keywords Arthritis · Rheumatoid · Patient-centered · Exercise · Fatigue · Depression · Anxiety · Metabolomics
Rheumatology
INTERNATIONAL 
 * Elvira Lange 
 elvira.m.lange@vgregion.se
 Daniel Kucharski 
 daniel.kucharski@vgregion.se
 Alastair B. Ross 
 Alastair.Ross@agresearch.co.nz
 Sara Svedlund 
 sara.svedlund@gu.se
 Caroline Feldthusen 
 caroline.feldthusen@vgregion.se
 Karin Önnheim 
 karin.onnheim@microbio.gu.se
 Kaisa Mannerkorpi 
 kaisa.mannerkorpi@neuro.gu.se
 Inger Gjertsson 
 inger.gjertsson@rheuma.gu.se
1 Rheumatology and Inflammation Research, Institute 
of Medicine, The Sahlgrenska Academy, University 
of Gothenburg, Gothenburg, Sweden
2 The Sahlgrenska University Hospital, Gothenburg, Sweden
3 Department of Health and Rehabilitation, Institute 
of Neuroscience and Physiology, The Sahlgrenska Academy, 
University of Gothenburg, Box 455, 405 30 Gothenburg, 
Sweden
4 University of Gothenburg Center for Person-centered Care, 
Gothenburg, Sweden
5 Department of Biology and Biological Engineering, 
Chalmers University of Technology, Gothenburg, Sweden
6 Protein and Metabolites Team, AgResearch, Lincoln, 
New Zealand
7 Department of Molecular and Clinical Medicine, Institute 
of Medicine, The Sahlgrenska Academy, University 
of Gothenburg, Gothenburg, Sweden
1586 Rheumatology International (2019) 39:1585–1594
1 3
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease characterized by joint pain, stiffness and inflammation 
of joint synovial tissue. In recent years, pharmacological 
treatments of RA have undergone revolutionary develop-
ments that have led to better control of inflammation and 
reduced joint destruction. The majority of the patients with 
RA, however, still suffer from fatigue [1], which they find 
to be a dominant and disturbing symptom [2–4]. There is 
currently no consensus definition of fatigue. Fatigue is 
acknowledged as a complex and subjective experience [5] 
and a commonly used description of fatigue is “an over-
whelming sustained sense of exhaustion and decreased 
capacity for physical and mental work” [6]. Fatigue is 
multi-factorial; in patients with RA it is partially depend-
ent on inflammation and production of pro-inflammatory 
proteins such as cytokines [7] and as in other conditions, 
can be related to inflammation-dependent anemia [8]. 
Fatigue correlates strongly with pain, depression [9–11] 
and sleep disturbances. Disability and psychosocial fac-
tors can also contribute [12]. The many effects of fatigue 
on the individual include disability, anxiety, reduced self-
efficacy, feelings of helplessness and limitations in social 
functioning [13]. Unsurprisingly, a third of RA patients 
also suffer from depression.
Mechanisms explaining the interaction between inflam-
matory conditions and fatigue have remained largely elu-
sive. Tools such as metabolomics can be used to explore 
the disease pathogenesis and generate new hypotheses for 
mechanisms based on the profile of small molecules in a 
sample. In blood plasma, the metabolites include organic 
acids, carbohydrates, amino acids and lipids, which 
together reflect many different metabolic pathways, and 
crucially, reflect the interaction between patient genetics, 
their environment, and the intervention. Metabolomics can 
be used to identify which pathways have been perturbed 
which is particularly relevant to patients with RA, for 
whom it has been shown that metabolites resulting from 
increased oxidative stress were most consistently associ-
ated with increased fatigue [14].
There is some evidence that increased physical activity 
can reduce fatigue and depression in younger patients with 
RA [15]. However, little is known about fatigue in relation 
to physical activity in older adults (> 65 years) with RA, an 
age group where the risk of increased in pain and fatigue in 
the implementation of an exercise program is a concern [16]. 
To overcome this hurdle we used a person-centered approach 
[17], with exercise developed together with the participant 
taking into account their limitations, resources and goals.
Here, we report the result of a secondary analysis 
of a randomized controlled multi-center trial, with the 
objective to study the effect of moderate-to-high inten-
sity aerobic and resistance exercise during 20 weeks, on 
fatigue and symptoms of anxiety and depression in older 
adults with RA.
Methods
This is a sub-study of a randomized controlled trial that 
evaluated the effect of 20 weeks moderate-to-high intensity 
exercise on older adults with RA [18]. The study partici-
pants were recruited from the Rheumatology clinics at the 
Sahlgrenska University Hospital, Gothenburg and Skaraborg 
Hospital, Skövde, Sweden, using the Swedish Rheumatology 
Quality Register (SRQ).
The participants were randomized, in blocks of 6 sub-
jects, by a person not involved in the examinations or inter-
ventions, using a computer-generated sequence concealed in 
sequentially numbered, sealed, opaque envelopes.
Study groups
The exercise group (n = 36) followed a gym-based exercise 
program with person-centered guidance from a physiothera-
pist three times a week together with light home-based exer-
cise for 20 weeks. The exercise consisted of moderate-to-
high intensity aerobic and resistance exercise with a total 
of 27 min of aerobic exercise and 5 resistance exercises 
for large muscle groups. The active control group (n = 38) 
performed light home-based exercise for mobility, lower 
body strength and balance, but no gym-based exercise for 
20 weeks. The exercise of both groups is described in detail 
elsewhere [18].
Patients
The participants were screened for eligibility by examination 
of their medical records, a telephone interview and a medi-
cal assessment. The medical assessment included physical 
examination, disease activity and blood samples. The flow-
chart of participant enrolment and follow-up, along with the 
details of tests of physical fitness, is presented elsewhere 
[18].
Inclusion criteria: RA according to the ACR 1987/
EULAR 2010 criteria; age ≥ 65  years; disease dura-
tion > 2 years; disease activity score 28 < 5.1. Exclusion cri-
teria: co-morbidities such as unstable ischemic heart disease 
or arrhythmia that might preclude moderate intensity exer-
cise; joint surgery within the 6 months prior to inclusion; 
ongoing exercise of moderate-to-high intensity ≥ 2 times/
week; inability to understand or speak Swedish; inability 
to participate in physical testing that involved walking or 
bicycling [18].
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There were 74 older adults with RA included in the 
study (Fig. 1). The exercise group (n = 36) and the active 
control group (n = 38) were considered equal in sociode-
mographic data [18]. All participants were invited to a 
post-treatment examination after 20 weeks and 100% 
(n = 36) in the exercise group and 97% (n = 37) in the 
active control group completed the test. At the 12 months 
follow-up the corresponding figures of attendance for 
assessment were 97% (n = 35) in the exercise group and 
95% (n = 36) in the control group.
Main outcome variable
Assessment of fatigue
Subjective fatigue was quantified using the Multidimen-
sional Fatigue Inventory (Swedish version) (MFI-20) 
[19]. Twenty statements were rated on a five-point Likert 
scale and divided into five subscales of fatigue: general 
fatigue, physical fatigue, mental fatigue, reduced activ-
ity, and reduced motivation. Scores range from 4 to 20 
for each subscale, with higher scores indicating a higher 
degree of fatigue [19]. Participants’ subjective experience 
of global fatigue was quantified using a Visual Analog 
Scale (0–100 mm)-Fatigue (VAS-F). The participants 
rated global fatigue during the previous week considered 
due to RA on a scale of 0 (no fatigue) to 100 (the most 
severe fatigue possible) [20, 21].
Assessment of anxiety and depression
Anxiety and depression was assessed using the Hospital 
Anxiety and Depression Scale-Swedish version (HADS). 
The scale is built up of the subscales anxiety (0–21) and 
depression (0–21). HADS contains 14 statements scored 
from 0 to 3, higher scores being indicative of higher degrees 
of distress [22]. A score of eight or above on any of the 
subscales has been suggested as a valid cut-off to identify 
anxiety or depression disorders, respectively [22, 23].
Measurement of plasma metabolomics
Fasting baseline and 20-week plasma samples (n = 48 sub-
jects) were used to understand potential metabolite associa-
tions with the intervention outcomes. Plasma metabolomics 
was measured using a previously validated gas chromatogra-
phy–mass spectrometry (GC–MS) method [24]. In brief, 100 
µL of plasma from fasting blood samples taken at baseline 
and at 20 weeks was extracted with 900 µL methanol:water 
(9:1 v/v), including a mix of internal standards, and a 200-
µL aliquot evaporated and derivatized using methoxymation 
and silylation. The metabolic profile was measured using 
GC–MS (Shimadzu TQ8030, Shimadzu Europa GmbH, 
Duisberg, Germany), and metabolites identified based on 
retention index and mass spectral matching.
Other variables
Disease activity was assessed using disease activity score 
28 (DAS28) [25]. Erythrocyte sedimentation rate (ESR), 
C-reactive protein (CRP) and hemoglobin (Hb) concentra-
tions were measured by the accredited routine laboratories 
for clinical chemistry at Sahlgrenska University, Gothen-
burg, and at Unilabs, Skövde. Participants’ objective experi-
ence of pain during the previous week considered due to RA 
was quantified using a Visual Analog Scale (0–100 mm) [21, 
26]. Demographic data were collected via a standardized 
interview. For the analysis of metabolomics, correlations 
with the variable of maximal oxygen consumption (VO2max) 
presented elsewhere are made [18].
Procedures
The participants were assessed at baseline, after 20 weeks 
and at follow-up after 12 months. All assessors were blinded 
to the treatment groups.
The study complied with the Declaration of Helsinki 
and was approved by the Regional Ethical Review Board in 
Gothenburg (2014-11-24/790-14). Informed, written con-
sent was obtained from the participants before the baseline 
examinations. The study was registered in ClinicalTrials.gov 
in March 19, 2015 (NCT02397798).
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Fig. 1  Assessment points of the study with assessed variables and 
participant flow. MFI Multidimensional Fatigue Inventory, VAS-F 
Visual Analog Scale Fatigue, HADS Hospital Anxiety Depression 
Scale, VAS-Pain Visual Analog Scale Pain, ESR erythrocyte sedimen-
tation rate, CRP C-reactive protein, Hb hemoglobin
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Statistical analysis
Comparison between groups was performed with the 
Mann–Whitney U test for non-parametric variables and 
Student’s t test for parametric variables using GraphPad 
Prism (GraphPad. San Diego. USA). p < 0.05 was consid-
ered as statistically significant. For comparisons within 
groups the Wilcoxon signed rank test was used. Baseline 
correlations between DAS28 and outcome variables were 
performed with Spearman’s correlation and a subgroup 
analysis was performed with DAS28 dichotomized as 
below 3.2 or 3.2 and above. The subgroup analysis was 
performed in the SPSS Statistics for Windows, Version 
24.0 (IBM corp., Armonk, NY, USA).
Metabolomics data were log-transformed and corrected 
for baseline (post-intervention values minus baseline val-
ues) to correct for inter-individual differences. Metabolic 
feature reduction was done using orthogonal projection 
to latent structures discriminant analysis (OPLS-DA) and 
partial least squares (PLS) in Simca (Umetrics AB, Umeå, 
Sweden). Differences in metabolic response between 
groups were identified using the General Linear Model, 
including change in VO2max (as a proxy for compliance) 
and analytical batch as covariates.
Analysis were performed on the association between 
metabolic profile changes (week 20 minus baseline val-
ues), with change in physical fatigue and change in maxi-
mum oxygen consumption (VO2max) reported previously 
[18]. Associations were determined using Pearson’s or 
Spearman’s correlation coefficient depending on whether 
or not the data were normally distributed, and relation-
ships reported if p < 0.05.
Results
Demographics and clinical characteristics are presented in 
Lange et al. 2019 [18]. In brief, in the intervention group 
75% were women with a mean age of 69.14 (SD 2.6) and in 
the control group, 76.3% were women, aged 70.11 (SD 3.10) 
at baseline. At baseline the variables MFI-20 general fatigue 
(r = 0.419, p < 0.001), MFI-20 physical fatigue (r = 0.421, 
p < 0.001) and the VAS-F variable (r = 0.454, p < 0.001) cor-
related with DAS28.
Two participants in the exercise group and four in the 
control group used sedatives and the use of sedatives did not 
change during the study. At baseline two participants in the 
exercise group and one in the control group used antidepres-
sant medication. After 20 weeks one of the participants in 
the exercises group had dimidiated the dosage and another 
two participants in the controls group had started on antide-
pressants (data not shown).
20‑week exercise reduced fatigue in older adults 
with RA
The subscales of MFI-20 physical fatigue (p = 0.002) and 
mental fatigue (p = 0.048) was significantly reduced at 
20 weeks in the exercise group when compared to the control 
group (Table 1). The remaining subscales of MFI-20, gen-
eral fatigue, reduced activity and motivation, remained unaf-
fected by exercise. Global fatigue reported using VAS-F did 
not significantly differ between exercise and control groups. 
The subgroup analysis based on dichotomization of DAS28 
found no significant differences between the exercise and 
control group. Within the exercise group there was a signifi-
cant difference in MFI-20 subscale physical fatigue both in 
the group with a low (n = 26, median Δ = − 2, ICR: − 3.25; 
− 1, p = 0.001) and a moderate disease activity (n = 27, 
median Δ = 0, ICR: − 1; 3, p = 0.041).
20‑week exercise alleviated symptoms 
of depression in older adults with RA
At 20 weeks, there was a significant (p = 0.039) reduction 
in symptoms of depression in the exercise group compared 
to the control group (Table 1). At baseline one participant 
in the exercise group and two participants in the control 
group scored HADS depression above the cut-off of 8 points. 
After 20 weeks these three individuals still scored above 
the cut-off and further one of the control group participants 
(data not shown). The subgroup analysis showed that within 
the exercise group with a low disease activity, symptoms 
of depressions were significantly improved (n = 27, median 
Δ = − 1, ICR: − 1; 0, p = 0.045) when compared to base-
line. At baseline six participants of the exercise group and 
seven participants of the control group scored above the 
cut-off of 8 points on HADS anxiety. After 20 weeks three 
of these participants in the exercise group and one in the 
control group had lowered their score below the cut-off (data 
not shown). However, there was no significant difference 
between groups in anxiety (Table 1).
20‑week exercise did not influence pain, disease 
activity or inflammatory markers in older adults 
with RA
The participants were considered to be equivalent in disease 
activity (DAS28) at baseline; 2.33 (SD 1.10) in the exercise 
group and 2.41 (SD 0.91) in the control group. After 20 weeks 
the disease activity was not significantly changed within or 
between groups with DAS28 in the exercise group at 2.27 
(SD 1.05) and in the control group 2.27 (SD 0.92). Hb was 
also equivalent at baseline 131.4 g/L (SD 11.6) in the exercise 
group and 131.1 g/L (SD 13.6) in the control group) and did 
not significantly change after the intervention. The participants 
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were considered to be equivalent in levels of inflammatory 
markers (CRP and ESR) and rated VAS-Pain at baseline [18] 
and there were no significant between- or within-group differ-
ences in these parameters at 20 weeks compared to baseline 
(data not shown).
Changes to physical fatigue in MFI‑20 and VO2max 
were associated with several metabolic changes
Based on targeted analysis of GC–MS data, 146 unique 
metabolites were identified in plasma samples from subjects 
in this study. Seventeen of these metabolites were significantly 
associated with changes in the MFI-20 physical fatigue scale, 
and aerobic capacity (VO2max) (Table 2). These metabolites 
represent diverse compound classes and metabolic pathways 
monosaccharides, bile acids and metabolites related to lipid 
metabolism and the urea cycle.
20‑week exercise reduced circulating concentrations 
of some lipids in older adults with RA
Twenty weeks of exercise led to decreases in plasma levels 
of 1-myristoyl-glycerol (p = 0.001), 24-methylcholesterol 
(p < 0.001), cholesterol (p = 0.046), campesterol (p < 0.001) 
and α-tocopherol (p = 0.003). Circulating levels of agmatine 
(p = 0.027) and phenylpyruvic acid (p = 0.020) were also 
increased in the intervention group (Table 3).
52‑week follow‑up
Withdrawal of the supervision of the exercise intervention 
program at 20 weeks resulted in the loss of the significant 
improvements in fatigue and depression recorded at that 
point in the study (Table 1). These findings coincide with 
diminished intensity and duration of exercise at 52 weeks 
[18]. Additionally, none of the outcomes from the assess-
ments for HADS anxiety, VAS-P, or the remaining MFI-20 
Table 1  Differences between groups in assessment measures at weeks 20 and 12 months compared to baseline
Variables are presented as medians (IQR)
MFI Multidimensional Fatigue Inventory, VAS-F Visual Analog Scale Fatigue, HADS Hospital Anxiety Depression Scale
Delta values were compared using the Mann–Whitney U test. Within-group comparisons were made with Wilcoxon
*Significant difference, p < 0.05
**Significant difference, p < 0.01
***Significant difference, p < 0.001
Intervention group (N = 36) Control group (N = 38) Between-group differ-
ences
Baseline Post-treat-
ment—base-
line
Follow-up—
baseline
Baseline Post-treat-
ment—base-
line
Follow-up—
baseline
Post-treat-
ment—base-
line
Follow-
up—
baseline
Δ 20-0 w Δ 52-0 w Δ 20-0 w Δ 52-0 w p value p value
MFI-20
 General 
fatigue
8 (6.3 to 13.8) − 1 (− 3 to 0) 0 (− 3 to 1) 12 (9.3 to 13.8) 0 (− 3 to 2) 0 (− 2 to 2) 0.345 0.952
 Physical 
fatigue
9 (6 to 13) − 2*** (− 3 to 
− 0.8)
− 2* (− 3.3 to 1) 10 (7.5 to 13.5) 0 (− 1.8 to 2) 0 (− 2 to 1) 0.002** 0.084
 Mental 
fatigue
8 (5 to 11) 0 (− 1.3 to 4) 0 (− 3 to 2) 9 (4.5 to 11) 0 (0 to 1) 0 (− 1 to 2) 0.048* 0.466
 Reduced 
motivation
6 (4 to 9) 0 (− 1 to 0.3) 0 (− 1 to 1) 7 (4 to 9.5) 0 (− 1 to 2) 1 (− 1 to 2)* 0.106 0.156
 Reduced 
activity
9 (5.3 to 13) − 1* (− 2 to 1) − 1 (− 3 to 0) 11 (7 to 13) 0 (− 1.3 to 2) 0 (− 2 to 2) 0.074 0.095
 VAS-F, 
0–100 mm
26 (7.3 to 50.5) − 2 (− 11.5 to 
4.8)
− 1 (− 16 to 8) 28.5 (9.8 to 42) 0 (− 11 to 11.8) − 3 (− 10 to 17) 0.355 0.707
HADS (0–21)
 Anxiety 2.5 (0.3 to 6.8) − 1 (− 2 to 0) 0 (− 1 to 1) 2 (1 to 6) 0 (− 1 to 1) 0 (− 1 to 1) 0.064 0.370
 Depression 2 (1 to 4) 0 (− 1 to 0)* 0 (− 1 to 0) 2 (1 to 4) 0 (− 0.5 to 2) 0 (− 1 to 1) 0.039* 0.328
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subscale categories (Table 1), was different at 52 weeks from 
the baseline readings. In the subgroup analysis the MFI-20 
subscale physical fatigue (median Δ = − 2, ICR: − 3.5; 0.5, 
p = 0.019) and reduced activity (median Δ = − 1.5, ICR: − 4; 
0, p = 0.013) were significantly improved within the exercise 
group with a low disease activity (n = 25) but not in the other 
groups.
Discussion
To our knowledge, this is the first study to show that 
moderate-to-high intensity exercise reduces physical and 
mental dimensions of fatigue and has positive effects on 
symptoms of depression in older adults with RA, at the 
same time recording significant associations between 
these changes and differences in plasma concentrations of 
Table 2  Correlations 
between change in 
physical fatigue or aerobic 
capacity, with change in 
metabolite concentrations 
between baseline and 20 weeks
Only statistically significant correlations are shown
Data on aerobic capacity from Lange et al. [18]
*Significant difference, p < 0.05
**Significant difference, p < 0.01
Metabolite Change in aerobic 
capacity
p value Change in physical 
fatigue
p value
Arabinose − 0.333 0.034*
Lyxose − 0.348 0.026*
Pyruvic acid − 0.327 0.037*
Agmatine − 0.317 0.043* 0.302 0.042*
Arginine − 0.410 0.008**
Cysteine − 0.324 0.039*
Indole-3-acetic acid − 0.307 0.051*
N-Acetylglutamic acid − 0.320 0.041*
Ribose − 0.353 0.024*
Gluconic acid 1,5-lactone 0.331 0.025*
24-Methylcholesterol 0.382 0.009*
Alpha-tocopherol 0.361 0.014*
Campesterol 0.403 0.006**
Deoxycholic acid − 0.304 0.040*
Glyceric acid 0.304 0.040*
Quinic acid − 0.314 0.034*
Sorbitol-6-phosphate 0.314 0.034*
Table 3  Metabolites 
significantly affected by exercise 
intervention at 20 weeks 
compared to baseline
SE standard error
*Significant difference, p < 0.05
**Significant difference, p < 0.01
***Significant difference, p < 0.001
All participants Intervention group (N = 24) Control group (N = 24) p value
Δ 20-0 w Δ 20-0 w
Mean SE Mean SE
1-Myristoyl-glycerol − 3782.99 1528.857 6807.943 1528.857 0.001**
24-Methyl-cholesterol − 1790.35 725.679 4112.523 725.679 < 0.001***
Agmatine − 83,912.7 25,804.98 33,310.1 25,804.98 0.027*
Alpha-tocopherol − 12,470.4 5794.299 23,300.33 5794.299 0.003**
Campesterol − 1385.58 833.4642 4547.694 833.4642 < 0.001***
Cholesterol − 42,907.5 23,636.28 53,526.94 23,636.28 0.046*
Phenylpyruvic acid − 19,582.9 7740.779 17,587.55 7740.779 0.020*
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metabolites from a wide range of compound classes and 
pathways, reflecting the wide-ranging effects of effective 
exercise on metabolic status. The exercise intervention 
led to significant improvement in aerobic capacity, endur-
ance and physical strength of participants [18], which have 
separately been found to reduce fatigue in people with RA 
or fibromyalgia less than 65 years of age [27, 28]. The 
observed effect of exercise on fatigue is to be contrasted 
with treatments that reduce disease activity profoundly, 
such as methotrexate and biologic/targeted synthetic dis-
ease modifying anti-rheumatic drugs (DMARDs), alone or 
in combination, as well as preventing joint destruction, but 
that only partly reduce [29] and seldom eliminate fatigue 
[1]. The participants in the present study were in remis-
sion or had low disease activity, but still scored clinically 
relevant fatigue (VAS > 20) [12]. Their exercise affected 
neither disease activity nor inflammatory markers [18, 30], 
yet contributed to a clinically relevant [31] reduction of 
physical fatigue, suggesting that it is relevant to evaluate 
non-pharmacological treatment options against fatigue in 
older adults with RA.
The subgroup analysis indicates that the participants with 
a lower disease activity at baseline got the best effects of 
moderate-to-high intensity exercise on fatigue and depres-
sion. Disease activity has been found to correlate with 
fatigue [32], but has not been documented as a stronger pre-
dictor for fatigue in RA [12, 33]. However, patients have 
described struggling with the unpredictability of the disease 
activity to be physically active [34] and reduced physical 
health is a barrier for exercise among older persons with 
RA [35].
Fatigue ratings by participants in this study were low 
relative to those reported by others [3, 36], one explanation 
for which could be selection bias; persons volunteering to 
participate in a study involving exercise 3 times a week are 
likely to be at the lower end of the fatigue spectrum for peo-
ple with RA. Nonetheless there was a significant decrease 
in physical and mental fatigue directly after the intervention 
period (at 20 weeks) in the intervention group compared to 
the control group. Physical and mental fatigue are defined 
here by their respective MFI-20 subscales; “physical fatigue” 
records the person’s feeling of physical wellness combined 
with their ability to perform different tasks, and is supposed 
to be related to significantly improved physical fitness in the 
participants in the intervention group [18]; “mental fatigue” 
on the other hand focuses on concentration and coping with 
thoughts. It is likely that the lessening of mental fatigue seen 
here is part of the alleviation of symptoms of depression 
rated with the HADS scale in the same participants. This 
provides at least a partial explanation of the positive effects 
of physical activity on depression found elsewhere [37–39], 
and reconfirms the link between fatigue and depression 
that has already been suggested [9]. A small minority of 
participants (3% of the intervention group and 5% in the con-
trol group at baseline) had symptoms of depression defined 
as HADS depression of more than 8 points. Nevertheless, 
the significant reduction of the HADS depression score in 
the intervention group at week 20 indicate that the mood of 
the participants was improved.
When the degree of exercise was reduced after 20 weeks 
the improvement in fatigue and symptoms of depression dis-
appeared, along with enhanced physical fitness; only endur-
ance was sustained to week 52 [18]. This outcome identifies 
a link between the supported maintenance of moderate-to-
high intensity exercise and its success in improving fatigue 
and depression, important determinants of quality of life of 
persons with RA [40], and should be taken into account in 
the design of therapies for the future.
We found no significant effects of exercise on either 
of the VAS-F or MFI-subscale “general fatigue” param-
eters, probably due to construction of the scales, as they 
rate global fatigue that may include several other feelings, 
such as pain and sleep. Neither were there significant dif-
ferences between the two groups after the intervention in 
the subscales “reduced activity” and “reduced motivation”, 
maybe reflecting a high degree of motivation in the selected 
cohort; in support of this possibility, the compliance with 
the study protocol was high and 98.6% of the participants 
completed the 20 weeks examination [18]. Both the selection 
of participants and the person-centered approach are likely 
to have contributed to this success [18]. Additionally, study 
participants were retired, and having fewer mandatory duties 
(working hours) and less demanding expectations from oth-
ers might help older adults to cope with fatigue more easily 
[41].
The metabolomic profiling included in this study revealed 
changes attributable to the exercise intervention in eight of 
the identified metabolites, with only one of these metabo-
lites also being significantly associated with the decrease in 
physical fatigue shown by the MFI-20 analysis. The meta-
bolic changes found in the current study were largely related 
to lipid and specifically sterol metabolism, where circulating 
concentrations of some lipids were lower in the interven-
tion group than in control group. Some of these are known 
to be diet-related (24-methylcholesterol, campesterol, and 
α-tocopherol); the exercise intervention may have led to 
modifications in participants’ food intake, or metabolism 
of these compounds may have increased. Exercise has else-
where been found to raise concentrations of campesterol 
and sitosterol concentrations, in association with improved 
VO2max [42]. α-Tocopherol has been found to increase in 
high-intensity exercise, though rapidly returns to normal 
concentrations on resting [43, 44]. As diet was not meas-
ured in this study, we can only speculate that physiological 
effects of exercise rather than dietary changed altered these 
lipids. Other studies using metabolomics to probe the effects 
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of exercise interventions report effects on lipid metabo-
lism, though often in addition to purine and central energy 
metabolism [45]. The association of pyruvic acid and ribose 
with VO2max suggests that both purine and central energy 
metabolism pathways were impacted by the intervention, in 
addition to the urea cycle, as demonstrated by the relation-
ship between both arginine and agmatine with change in 
VO2max. These data suggest that the exercise intervention 
led to general metabolic changes that are consistent with the 
previous literature on exercise interventions, suggesting that 
RA does not alter metabolic response to exercise.
Especially for the metabolomics analysis, the low over-
all number of subjects and free-living nature of the current 
study are likely to be the cause of a considerable degree of 
inter-individual variation and potential confounding from 
lifestyle factors that have not been measured here. We also 
noted that there were significant gender effects which should 
be accounted for (data not shown). To control for this, future 
studies would benefit from including more subjects and 
using lipidomics analysis (methodology that focuses specifi-
cally on the lipid fraction of blood), since lipid metabolism 
appeared to be widely affected by exercise here, and many 
lipids play a role in inflammation pathways. This explora-
tory component of this study suggests that there are sev-
eral metabolic changes related to improvement in physical 
fatigue in RA, and the use of such biomarkers will become 
increasingly useful in the tailoring of therapies including 
supervised exercise to individuals who are likely to see the 
greatest benefit.
Fatigue and depression are subjective symptoms with 
multi-factorial causes; for instance it has been observed 
that persons with RA suffer more with fatigue during the 
winter [46]. In documenting the lessening of fatigue and 
depression resulting from exercise, independent of disease 
status, this report emphasizes the importance of multi-modal 
approaches to both pharmacological and non-pharmaco-
logical aspects of treatment; understanding mechanisms 
may help to guide multi-pronged approaches to therapy for 
patients with RA.
Limitations
The studied population was highly selected [18] and there-
fore not representative for all older adults with RA. Most of 
the participants’ had low disease activity and were positive 
about participating in a study regarding physical activity. 
Alongside this it would have been of interest to compare 
moderate-to-high intensity exercise not only with low-
intensity exercise but with a control group performing no 
exercise. The study lacks logs of the participants’ sleep and 
self-reporting sleeping questionnaires concerning the par-
ticipants’ sleeping habits that could have contributed to the 
understanding of changes in fatigue.
With the present study being a secondary analysis, power 
was calculated based on primary outcome of the primary 
analysis previously published [18]. The number of partic-
ipants was considered to be sufficient for the aim of this 
analysis and the significant results indicate that they were.
Conclusion
Person-centered moderate-to-high intensity exercise 
decreased fatigue and lessened symptoms of depression 
in older adults with RA, improvements that were accom-
panied by metabolic changes. Our study strongly suggests 
that moderate-to-high intensity exercise should be imple-
mented in standard care in older adults with RA. Further, 
to maintain the beneficial effects, the exercise needs also to 
be maintained.
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